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Epilepsy is a severe brain disorder affecting numerous patients. Recently, it is inferred
that modulation of microRNA-155 (miR-155) could serve as a promising treatment of
mesial temporal lobe epilepsy. In the current study, the therapeutic potential of miR-
155 antagonist against temporal lobe epilepsy (TLE) was evaluated and the underlying
mechanism involved in this regulation was explored. TLE model was induced by
lithium-pilocarpine method. The effect of miR-155 antagonist on epilepticus symptoms
of TLE mice was assessed using Racine classification and electroencephalogram
(EEG) recordings. The expression of brain-derived neurotrophic factor (BDNF) and
its association with miR-155 were also assessed with a series of experiments. Our
results showed that level of miR-155 was significantly up-regulated after induction of
TLE model. Based on the results of EEG and behavior analyses, seizures in mice
were alleviated by miR-155 antagonist. Moreover, administration of miR-155 antagonist
also significantly increased the level of BDNF. The results of dual luciferase assay
and Western blotting showed that miR-155 antagonist exerted its action on status
epilepticus by directly regulating the activity of BDNF. Taken all the information together,
our results demonstrated that miR-155 antagonist might firstly induce the expression of
BDNF, which then contributed to the alleviation of epilepsy in the current study.
Keywords: antagonist, brain-derived neurotrophic factor, epilepsy, microRNA-155, lithium-pilocarpine
INTRODUCTION
Epilepsy is a serious chronic and debilitating brain disorder characterized by paroxysmal bursts
of activity within cortical neurons (Matsumoto and Marsan, 1964). Although epilepsy frequently
occurs in childhood, it can affect people of whole age (Huang et al., 2015). Patients with epilepsy
are generally impaired by intermittent infuriation in movement, feeling, or consciousness which
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is caused by the suddenly synchronous and excessive discharges
in cortical neurons (Brodie and French, 2000). Currently,
resective surgeries for focal epilepsy and new-generation
antiepileptic drugs (AEDs) are the major treatments for patients
with epilepsy (Kawai, 2015). However, both methods have some
following side effects such as headache, dizziness, fatigue, and
ataxia (Brodie and Dichter, 1996). Additionally, more than
20% of epilepsy patients continue to suffer from seizures even
after being subjected to above mentioned therapies. Thus,
identification of some novel biological markers for development
of therapeutic strategies against epilepsy is demanding prompt
solution.
With the development of genetic discoveries and
genetic techniques, molecular causes of epilepsy has been
comprehensively revealed during the past several years (Buiting
et al., 1995; Buiting, 2010; Lee and Heo, 2014; El Achkar et al.,
2015). Emerging evidence infers the participation of microRNAs
(miRs) in the lesion of types of epilepsy (Li et al., 2014). MiRs
belong to an endogenous class of small non-coding RNAs
and take their actions through inhibition of translation levels
of specific genes or fracture of targeted mRNAs (Schirle and
MacRae, 2012). Members of miRs play crucial roles in the
regulation of gene expressions and functional gene networks
(Schratt, 2009). The involvement of miRs in neurological diseases
has been highlighted: in response to brain injuries such as acute
neurological disorders and prolonged seizures, the levels of
several miRs alter chronically (Aronica et al., 2010; Liu et al.,
2010; Hu et al., 2011). Therefore, potency of miRs as clinical
biomarkers for detection of neurological diseases is extensively
investigated (de Planell-Saguer and Rodicio, 2011). For studies
regarding roles of miRs in epilepsy, understating the changing
pattern and therapeutic potential of these indicators has become
central subjects. In recent study of Jimenez-Mateos et al. (2015),
the authors have demonstrated the vital function of miR-134 in
alleviating pilocarpine-induced status epilepticus: the research
provides compelling evidence that application of antagonist
against miRs significantly suppresses seizures in an animal
model. Furthermore, another multifunctional miR, miR-155, is
proved to possess the capability to mediate acute inflammatory
response associated with activation of Toll-like receptors that is
a suspected feature of epilepsy onset (Tili et al., 2007; Maroso
et al., 2011). The role of miR-155 in mesial temporal lobe
epilepsy (MTLE) is also verified in the study of Ashhab et al.
(2013), which infers that modulation of miR-155 may be an
alternative therapy for treatment of MTLE. Moreover, miR155 is
capable of modulating the activity of brain-derived neurotrophic
factor (BDNF) that is critical to the normal development of
the CNS and contributes to the development of temporal
lobe epilepsy (TLE; Scharfman, 2005; Varendi et al., 2014).
Such interaction between miR-155 and BDNF may represent a
potential mechanism through which miR-155 functions on the
onset of epileptic disorders. However, unlike studies on miR-134,
the potential of miR-155 as a novel therapeutic target for epileptic
disorders is only partially revealed. Considering the determinant
role of miR-155 in numerous biological processes, it is reasonable
to explicitly explore the function of miR-155 in epilepsy and to
assess its regulation as an anti-epilepsy strategy.
In the present study, TLE model was induced by lithium-
pilocarpine method. Thereafter, expressions of miR-155 at mRNA
and protein levels were detected with quantitative real-time
PCR (qPCR) and Western blotting assay. The effect of miR-155
antagonist on epilepsy mice was evaluated by behavior analyses
and electroencephalogram (EEG) recording. The expression of
BDNF and its connection with miR-155 production in epilepsy
were also determined. Findings in the present study could
assess the potential of miR-155 modulation as a novel anti-
epilepsy therapy and provide a preliminary explanation on the
mechanism driving the alleviative effect of miR-155 antagonist
against epileptic disorders.
MATERIALS AND METHODS
Chemicals and Animals
Lithium, pilocarpine, scopolamine, and diazepam were
purchased from Sigma Chemical, Co. (Calt. No. L4408-100G,
P6503-5G, S8502-1G, D0899, St. Louis, MO, USA). MiR-155
antagonizing sequence and a non-targeting scrambled version
of the antagonist were purchased from GenePharma, Co. Ltd.,
(Shanghai, China). Antibodies against BDNF and β-actin were
purchased from Santa Cruz (Calt. No. sc-546 and No. sc-47778,
Shanghai, China). 8-weeks-old male C57BL/6 mice (weighing
from 18 to 25 g) were provided by Experimental Animal Center
of China Medical University and housed in cages at 20–25◦C
with a constant humidity (55 ± 5%) with water and food
available ad libitum. All animal experiments were conducted in
the accordance with the Institutional Animal Ethics Committee
and Animal Care Guidelines for the Care and Use of Laboratory
Animals of The First Affiliated Hospital of Dalian Medical
University.
Animal Grouping and Induction of TLE
Models
Forty-eight mice were employed and randomly divided into four
groups (12 for each group): (A) Control group, healthy C57BL/6
mice. (B) TLE group, mice underwent surgical processes to
induce TLE. (C) CK group, TLE mice pre-treated with 0.12 nmol
non-targeting antagonist (2µL). (D) Antagonist group, TLE mice
pre-treated with 0.12 nmol miR-155 antagonist (2 µL). For TLE
induction, mice were anesthetized with pentobarbital sodium
(50 mg/kg) and placed in stereotaxic frame. After a midline
incision, a guide cannula was affixed to the surface of the brain for
the intracerebroventricular injection (coordinates from Bregma
were AP, −0.3 mm; L = −1.0 mm; and V = −2.0 mm). Mice
in CK and antagonist groups were received injection of specific
agents while mice in the other two groups received artificial
cerebrospinal fluid (2 µL) instead. 24 h later, mice in TLE,
CK, and antagonist groups were administrated with 3 mEq/kg
lithium for 18 h and then subcutaneously injected with 1 mg/kg
scopolamine. After additional 30 min, 340 mg/kg pilocarpine was
intraperitoneally injected into mice in TLE, CK, and antagonist
groups to induce epilepsy. 90 min after seizure attack, mice in
TLE, CK, and antagonist groups were given 6 mg/kg diazepam
to curtail seizures and reduce morbidity and mortality. For mice
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in Control group, all the injections were performed with same
volume of saline at the same time points. Afterward, all the
mice were raised under the same condition. Mice in Control
and TLE groups were used for qPCR detection: six randomly
selected mice in each group were sacrificed 4 and 12 h after model
establishment, respectively and brain tissues were collected for
qPCR validation of miR-155 expression as described following.
Mice in CK and antagonist groups were housed for 7 days
to determine the effect of antagonist on the survival of mice.
Another 24 mice were grouped as described above (six for each
group) for detection of association between miR-155 and BDNF.
The detail experimental design was shown in Supplementary
Figure S1.
Quantitative Real-Time PCR
For qPCR detection, whole RNA in brain tissues from mice
was extracted using RNA simple Total RNA Kit according
to the manufacturers’ instruction (Calt. No.DP419, TIANGEN,
Beijing, China). β-actin was selected as the internal reference
gene. Then the whole RNA was reversely transcribed to
cDNA templates using Super M-MLV reverse transcriptase
(Calt. No. RP6502, BioTeke, Beijing, China). The final qPCR
reaction mixture of volume 20 µL consisted of 10 µL of
SYBR GREEN mastermix, 0.5 µL of each primers (miR-155,
forward: 5′-CAGCCTACACGGTGGGAGC-3′, reverse: 5′-CT
GCTCTGAGTCATTGTGCTGG-3′; BDNF, forward: 5′-GGT
GGTGTAAGCCGCAAAG-3′, reverse: 5′-GTGTCAGCCAGTG
ATGTCG-3′; β-actin forward: 5′-CTTAGTTGCGTTACACCCT
TTCTTG-3′, reverse: 5′-CTGTCACCTTCACCGTTCCAGTTT-
3′), 1 µL of the cDNA template, and 8 µL of RNAse free
H2O. Amplification parameters were as follows: denaturation at
95◦C for 10 min, followed by 40 cycles at 95◦C for 10 s, 60◦C
for 20 s, and 72◦C for 30 s. Relative expression levels of the
targeted molecules were calculated with Data Assist Software
version 3.0 (Applied Biosystems/Life Technologies) according to
the expression of 2−11ct.
Electroencephalogram (EEG) and
Behavior Analyses
For recoding of EEG, experimental mice were anesthetized with
pentobarbital sodium (50 mg/kg) and placed in stereotaxic frame.
Two skull-mounted recording electrodes were subcutaneously
placed in the bregma and occiput of the left ear of the
mouse, and another skull-mounted recording electrode was
placed on right ear of the mouse. All the electrodes were
assembly fixed in place with dental cement during the surgical
process. Animals were housed under the same condition
and EEGs of mice were recorded and analyzed using BL-
420F Biological Functional System (Techman Soft, Chengdu,
China) 4 h and 3 days after model establishment according
to the manufacturer’s instruction. The differences in spike and
frequency between different groups were analyzed. Three days
after model establishment, the severity of convulsions of mice
in each group was analyzed using Racine classification (Racine,
1972) following procedures of previous study in a blind fashion
(Jimenez-Mateos et al., 2015). Then mice were sacrificed and
brain tissues were collected for histological and molecular
analyses.
Western Blotting
The whole protein product in different groups was extracted
using the Total Protein Extraction Kit according to the
manufacturer’s instructions (Catl. No. WLA019, Wanleibio,
China). β-actin was used as the internal reference. Concentration
of protein samples was determined using the BCA method.
20 µL of protein (40 µg) was subject to a 10% sodium
dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE).
Targeted proteins were transferred onto polyvinylidene difluoride
(PVDF) sheets and the membranes were washed with TTBS for
5 min before incubation in skim milk powder solution for 1 h.
Primary antibodies against BDNF (1:200) or β-actin (1:1000)
were incubated with membranes at 4◦C overnight. After four
washes using TTBS, secondary HRP IgG antibodies (1:5000)
were added into the mixture and incubated with the membranes
for 45 min at 37◦C. After additional six washes using TTBS,
the blots were developed using Beyo ECL Plus reagent and the
results were detected in the Gel Imaging System. The relative
expression levels of BDNF in different samples were calculated
with Gel-Pro-Analyzer (Media Cybernetics, USA).
Immunohistochemical Detection
For immunohistochemical (IHC) detection, brain sections from
different groups were placed in 60◦C for 2 h before incubation
with dimethylbenzene for dewaxing. The slides were hydrated
with alcohol. Slides from different groups were fixed using
methanol solution with 3% H2O2 and blocked with 1% goat
serum for 15 min at room temperature. Primary anti-BDNF
antibody (1:50) was added and incubated at 4◦C overnight. After
three cycles of 0.01 M PBS wash, 5 min for each cycle, secondary
antibody (1:200) was added to the slides and placed at 37◦C for
30 min before another three cycles of PBS wash. Slides were then
incubated with HRP at 37◦C for 30 min before three cycles of 5-
min PBS washing. Then DAB was added to the slides and reacted
for 3–10 min until the reaction was stopped by ddH2O. Slides
were re-stained using hematoxylin and dehydrated. Percentage of
positively stained cells and the staining intensity of the different
groups were determined by observation under a microscope at
400×magnification.
Regulation of BDNF by miR-155 in Mice
Neuron Cells
Mice neuron cells were collected from fresh cerebral cortices
of the newborn C57BL/6 mice and cultured routinely. p-EGFP-
miR-155 (expression Vector of miR-155), control p-EGFP
plasmid, and mutant p-EGFP-miR-155 were obtained from
Genechem Biotech (Shanghai, China). Moreover, a fragment
of the 3′ UTR of BNDF cDNA was inserted into pGL3
vector (vector containing firefly luciferase under the control
of SV40 promoter, Promega) to form pGL3-BDNF plasmid.
Concentration of mice neuron cells was adjusted to 1 × 104/mL
and incubated on slides for 24 h before co-transfection with
different combinations of vectors using Lipofectamine 2000
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reagent (Invitrogen) according to the manufacturer’s protocol,
and subsequent selection was conducted using 400-µg/mL
puromycin (Amresco, Solon, OH, USA). Grouping of cells were
as following: (A) pGL3+p-EGFP group; (B) pGL3+p-EGFP-
miR-155 group; (C) pGL3+mutant p-EGFP-miR-155 group; (D)
pGL3-BDNF+p-EGFP group; (E) pGL3-BDNF+p-EGFP-miR-
155 group; (F) pGL3-BDNF+mutant p-EGFP-miR-155 group.
Dual luciferase assay was conducted to measure the firefly
luciferase activity using Luciferase Report Gene Assay Kit (E1910,
Promega). Then the activities of BDNF in healthy neuron cells,
cells transfected with p-EGFP-miR-155 (expression Vector of
miR-155), and cells transfected with p-EGFP plasmid were
determined with qPCR and Western blot as described above.
Statistical Analysis
All the data were expressed in the form of mean ± SD. ANOVA
and Post doc multiple comparisons using LSD method were
FIGURE 1 | Induction of TLE up-regulated the transcription of miR-155
and the effect was time-dependent. “a” significantly different from Control
4 h, P < 0.05. “b” significantly different from TLE 4 h, P < 0.05. “c”
significantly different from Control 12 h, P < 0.05.
conducted using a general liner model (GLM). Two-group
data were compared using Student’s t-test. Difference between
proportions of survival mice in Control and TLE groups was
analyzed with a log-rank test. Significance was accepted at
P< 0.05. All the statistical analysis and graph manipulation were
conducted using GraphPad Prism 6 (GraphPad Software, San
Diego, CA, USA).
RESULTS
Induction of TLE Up-Regulated the
Expression of miR-155 In Vivo
The expression of miR-155 was firstly investigated with mice from
Control and TLE group at two time points. For brain tissues
sampled 4 h after model establishment, there was significantly
difference between the relative expression values of the two
groups (P < 0.05; Figure 1). For brain samples from 12 h
after TLE induction, the average miR-155 level in TLE group
was higher than that in Control group, and the difference
was statistically significant (P < 0.05; Figure 1). In addition,
the inducing effect of TLE on miR-155 expression was time
dependent in that the difference between samples from two
time points in TLE group was statistically different (P < 0.05;
Figure 1).
Administration of miR-155 Antagonist
Reduced Mice Mortality Caused by TLE
Survival curves of mice in CK and antagonist groups were
shown in Figure 2A. In CK group, only three mice survived
until the 7th day after TLE induction. Contrary to the result
of CK group, seven mice in antagonist group survived to the
ending point of the detection. Although, the survival difference
between the two groups was not statistically different based on the
analysis of log-rank test (P = 0.053), the results still indicated the
potential of miR-155 antagonist to reduce TLE-induced mortality
in mice.
FIGURE 2 | Administration of specific miR-155 antagonist improved the survival rate and seizures in TLE mice. (A) Comparison of survival curves
between antagonist and CK group, treatment of miR-155 antagonist increased the survival rate of TLE mice; (B) quantitative analysis results of Racine scores,
treatment of miR-155 antagonist decreased the seizures in TLE mice. “a” significantly different from Control group, P < 0.05. “b” significantly different from TLE
group, P < 0.05. “c” significantly different from CK group, P < 0.05.
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FIGURE 3 | Administration of miR-155 antagonist up-regulated the expression of BDNF. (A) Quantitative analysis results of qPCR validation of miR-155.
(B) Quantitative analysis results of qPCR validation of BDNF, treatment of miR-155 antagonist increased the production of BDNF at mRNA level. (C) Quantitative
analysis results and representative images of Western blotting assay of BDNF, treatment of miR-155 antagonist increased the production of BDNF at protein level.
(D) Quantitative analysis results and representative images of IHC assay of BDNF, the BDNF positive-stained cells were characterized by brownish-yellow particles
and treatment of miR-155 antagonist increased the production of BDNF. “a” significantly different from Control group, P < 0.05. “b” significantly different from TLE
group, P < 0.05. “c” significantly different from CK group, P < 0.05. Scale bar: 50 µm.
Administration of miR-155 Alleviated
Epilepticus Symptoms Related to TLE
Seizure behavior after TLE induction was analyzed using a Racine
scale. Three days after model establishment, TLE mice injected
with miR-155 antagonist displayed significantly reduced seizure
scores compared with those received saline or non-targeting
antagonist injections (Figure 2B). No significant difference was
detected for the average scores between mice in TLE and CK
groups.
The results of EEG recordings were recorded and shown
in Supplementary Figure S2 and Supplementary Table S1. No
significant effect of miR-155 antagonist on the brain activity of
TLE mice could be observed based on data derived from 4 h. For
recordings 3 days after TLE induction, it was demonstrated that
brain activities of miR-155 antagonist treated mice was similar to
that of health mice Although EEG detection didn’t provide solid
evidence in differentiating TLE from non-TLE cases, it might
suggest some difference in the posterior background activities
in brains of miR-155 antagonist treated mice as compared to
those with TLE (Supplementary Figure S2 and Supplementary
Table S1).
Administration of miR-155 Antagonist
Up-Regulated the Expression of BDNF
Both at mRNA and Protein Levels
As shown in Figures 3A,B, the pre-treatment of miR-155
antagonist led to increase in the transcription BDNF. The
relative expression of BDNF in antagonist group was ca.
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FIGURE 4 | Overexpression of miR-155 in neuron cells inhibited the expression of BDNF. (A) Quantitative analysis results of dual luciferase assay. (A)
pGL3+p-EGFP group; (B) pGL3+p-EGFP-miR-155 group; (C) pGL3+mutant p-EGFP-miR-155 group; (D) pGL3-BDNF+p-EGFP group; (E)
pGL3-BDNF+p-EGFP-miR-155 group; (F) pGL3-BDNF+mutant p-EGFP-miR-155 group. (B) Quantitative analysis results of qPCR validation of BDNF,
overexpression of miR-155 inhibited the production of BDNF at mRNA level. (C) Quantitative analysis results and representative images of Western blotting assay of
BDNF, overexpression of miR-155 inhibited the production of BDNF at protein level. For dual luciferase assay, “a” represents significantly different from
pGL3+p-EGFP group, P < 0.05. For qPCR and Western blotting assays, “a” represents significantly different from Control group and “b” represents significantly
different from Vector group, P < 0.05.
twofold higher than those in TLE and CK groups, and the
difference was statistically significant (P < 0.05). Similar pattern
was also observed in Western blot (Figure 3C). For IHC
detection, the BDNF positive-stained cells were characterized by
brownish-yellow particles and the expression of the indicator
were up-regulated in miR-155 antagonist treated group, which
was identical to the results of qPCR and Western blotting
(Figure 3D). To further explain the modulation of miR-155 on
BDNF, a dual luciferase assay was conducted. Reporter assay
revealed that overexpression of miR-155 significantly suppressed
the activity of BDNF plasmid in neuron cells (P < 0.05;
Figure 4A), indicating that miR-155 directly modulate BDNF
expression by binding to 3′ UTR of the gene. The detection
of BDNF production in neuron cells using qPCR and Western
blotting also drawn similar conclusions as that of dual luciferase
assay. At mRNA level, overexpression of miR-155 in cells
inhibited the expression of BDNF (Figure 4B), and the difference
between Control group and miR155 overexpressed group was
statistically significant (P < 0.05). Additionally, at protein level,
the redundant expression of miR155 resulted in a significant
decrease of BDNF expression compared with that in Control
group (P < 0.05; Figure 4C).
DISCUSSION
MiR-155 is a typical multifunction miR and plays crucial roles
in numerous biological processes (Faraoni et al., 2009). Plenty
of effect has been made to investigate the function of miR-
155 in neoplastic, cardiovascular, and viral infection diseases
(Esquela-Kerscher and Slack, 2006; Martin et al., 2007; Tili et al.,
2007), results of which imply the great value of miR-155 for
developments of novel treatment modalities against types of
devastating diseases. Thus, in the present study, the dynamic
expression of miR-155 in a lithium-pilocarpine-induced TLE
mice model and the potential of miR-155 as a promising therapy
against epilepsy were explored. It was found that inhibition
of miR-155 with specific antagonist resulted in the alleviation
of seizure behavior induced by TLE induction and reduced
mortality in TLE mice. Moreover, our data also evidently
showed that blocking or overexpression of miR-155 altered the
production of BDNF, representing a close association between the
two indicators in the onset of epilepsy.
Previous study of Jimenez-Mateos et al. (2015) reported
that in vivo silencing of miR-134 resulted in a potent
anticonvulsant effect through increasing volume of neuron spines
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in hippocampal CA3 pyramid, inferring the involvement of miRs
in the pathophysiology of epilepsy. In the present study, the
level of miR-155 was significantly up-regulated by TLE induction,
which supported the conclusion that expression of miR-155 was
abnormally high in patients of MTLE (Ashhab et al., 2013). Based
on the EEG and behavior analyses, up-regulation of miR-155
in TLE mice was accompanied by the deterioration of the EEG
performance and seizure features. Fortunately, in mice treated
with miR-155 antagonist, the onset of seizures was delayed and
the seizure power was reduced as well, representing an effectively
anticonvulsant capability of miR-155 antagonist.
Although, results in the current study cannot explicitly explain
the mechanism driving the anticonvulsant effect of miR-155
antagonist, it might highlight some aspects which had been long
ignored. As shown by the detection of BDNF in TLE mice, a
negative regulating effect of miR-155 on BDNF was validated.
This result was contrary to some reports regarding the role
BDNF in epilepsy (Heinrich et al., 2011; Wang et al., 2011).
Previous studies demonstrated an increase of BDNF in epilepsy
patients: the molecule could induce epileptogenesis by selectively
activating pathways such as TrkB signaling (Heinrich et al., 2011).
BDNF is a member of the neutrophin family of growth factors
and involved in numerous aspects of development, degeneration,
and differentiation of central nervous system (Tongiorgi et al.,
2004). MiRs including miR-155 are capable of directly repressing
BDNF through binding to their predicted sites in BDNF 3′
UTR (Varendi et al., 2014). In the current study, the abnormally
high level of BDNF in epilepsy patients and the negative
regulation of miR-155 on BDNF were verified. However, taken
this information together, it seemed that the study had come
to a dead end based on the existing theories. According to the
results of EEG and behavior analyses, the up-regulation of BDNF
by miR-155 antagonist was associated with the amelioration
of seizures, representing a paradox considering the formerly
reported expression pattern of BDNF in epilepsy (Heinrich
et al., 2011; Wang et al., 2011). Nevertheless, up-regulation
of BDNF might also be a contributor to the alleviation of
epilepsy. Although, a correlation between seizure activity in TLE
patient brains and BDNF production existed, this might represent
a BDNF-dependent activation of neuropeptide Y (Takahashi
et al., 1999). Level of neuropeptide Y increases in various
brain regions after limbic seizures and has an anticonvulsant-
activity in experimental animals (Bellmann et al., 1991; Erickson
et al., 1996; Woldbye et al., 1997). Since, this increase in
neuropeptide Y was preceded by increase of BDNF after seizures,
miR-155 antagonists might exert their function by activating
BDNF expression and subsequently inducing neuropeptide Y
production.
Both in vivo and in vitro experiments were performed to
assess the potential of miR-155 as an anticonvulsant target in
the present study. Based on our findings, considerable improving
effect of miR-155 antagonist on seizures was detected and it
was hypothesized that miR-155 antagonist might firstly induce
the expression of BDNF and then increase the synthesis of
neuropeptide Y to protect brain tissues from the impairments
of epileptogenesis. However, other mechanisms involved in this
treatment might also exist. To further promote the application
of specific miR antagonists in treatment of brain disorders, more
comprehensive work needed to be conducted in the future.
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